Variables | Free survival at 60 months (%) | Exp(B), CI 95%; p value |
---|---|---|
Age (years) | ||
< 58 | 89.7 | |
>58 | 68.4 | 0.460 (0.109-1.702); 0.160 |
Gender | ||
Male | 82.0 | |
Female | 80.0 | 1.676 (0.261-10.22); 0.601 |
Tumour localization | ||
OC + Or a | 73.1 | (avs.b) 2.166 (0.306-13.04); 0.524 |
L + H b | 100 | (avs.c) 1.146 (0.281-4.712); 0.845 |
N + U/M c | 84.4 | (bvs.c) 0.960 (0.101-9.101); 0.970 |
RT schedule | ||
Conventional | 88.9 | |
Hyperfractionated | 77.6 | 3.950 (0.955-13.88); 0.058 |
CMT | ||
Yes | 87.2 | |
No | 80 | 0.755 (0.188-2.926); 0.669 |
Surgery | ||
Yes | 94.7 | |
No | 76.8 | 3.910 (0.670-11.16); 0.161 |
Amifostine | ||
Yes | 81.5 | |
No | 85.5 | 0.617 (0.071-3.726); 0.510 |
β 24 | ||
< 11.32 | 92.9 | |
> 11.32 | 73.9 | 0.224 (0.060-0.904); 0.035 |